Myasthénie auto-immune induite par le nivolumab, un inhibiteur de checkpoint immunitaire

Sweis, 2017, Mechanistic and pharmacologic insights on immune checkpoint inhibitors, Pharmacol Res, 120, 1, 10.1016/j.phrs.2017.03.012 Postow, 2018, Immune-related adverse events associated with immune checkpoint blockade, N Engl J Med, 378, 158, 10.1056/NEJMra1703481 Cuzzubbo, 2017, Neurological adverse events associated with immune checkpoint inhibitors: review of the literature, Eur J Cancer Oxf Engl 1990, 73, 1 Spain, 2017, Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature, Ann Oncol, 28, 377, 10.1093/annonc/mdw558 Psimaras, 2019, Immune checkpoint inhibitors-induced neuromuscular toxicity: from pathogenesis to treatment, J Peripher Nerv Syst JPNS, 10.1111/jns.12339 Johnson, 2019, Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study, J Immunother Cancer, 7, 134, 10.1186/s40425-019-0617-x Wolchok, 2010, Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials, Cancer Immun, 10, 9 Suzuki, 2017, Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan, Neurology, 89, 1127, 10.1212/WNL.0000000000004359 Takamatsu, 2018, Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia, Ann Clin Transl Neurol, 5, 1421, 10.1002/acn3.654 Chen, 2017, Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review, Medicine (Baltimore), 96, e9262, 10.1097/MD.0000000000009262 Touat, 2018, Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer, Neurology, 91, e985, 10.1212/WNL.0000000000006124 Hua, 2016, Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab, JAMA Dermatol, 152, 45, 10.1001/jamadermatol.2015.2707 Anquetil, 2018, Immune checkpoint inhibitor-associated myositis, Circulation, 138, 743, 10.1161/CIRCULATIONAHA.118.035898 Friedman, 2016, Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review, JAMA Oncol, 2, 1346, 10.1001/jamaoncol.2016.1051 Touat, 2017, Neurological toxicities associated with immune-checkpoint inhibitors, Curr Opin Neurol, 30, 659, 10.1097/WCO.0000000000000503 Del Castillo, 2016, The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma, Clin Infect Dis, 63, 1490, 10.1093/cid/ciw539 Leonardi, 2018, Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders, J Clin Oncol, 36, 1905, 10.1200/JCO.2017.77.0305